(Soumyabrata Roy / NurPhoto via Getty Images) |
By Carrie N. Baker | Fifty-three biotechnology industry leaders and investors representing dozens of companies and organizations issued a letter late last month advising the U.S. Food and Drug Administration: Follow the science on mifepristone, not political ideology.
The Biotech CEO Sisterhood initiated the letter, with Grace Colón as lead author and dozens of senior biotechnology leaders signed on in support. “We are urging the agency and the department to continue to follow the science,” said Colón, who warned that political interference in drug regulation undermines both public trust and the FDA’s authority. (Click here to read more) |